[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336447-105":59,"doc-detail-336447-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","acute-ischaemic-stroke-in-active-cancer-versus-non-cancer-patients-stroke-characteristics-mechanisms-and-clinical-outcomes","Acute ischaemic stroke in active cancer versus non-cancer patients: stroke characteristics, mechanisms and clinical outcomes","","Demographics, clinical characteristics, stroke mechanisms and long-term outcomes were compared between acute ischaemic stroke (AIS) patients with active cancer and those without cancer. A retrospective cohort used data from 2003–2021 in the Acute STroke Registry and Analysis of Lausanne, excluding inactive cancer, with propensity score matching. Active cancer patients were older, had fewer vascular risk factors, received reperfusion less often, showed similar 3-month functional status, and had higher 12-month death and cerebrovascular recurrence risk. Antithrombotic treatment at discharge may lower risk.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/acute-ischaemic-stroke-in-active-cancer-versus-non-cancer-patients-stroke-characteristics-mechanisms-and-clinical-outcomes/336447/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/acute-ischaemic-stroke-in-active-cancer-versus-non-cancer-patients-stroke-characteristics-mechanisms-and-clinical-outcomes/336447.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main goal?","Question",{"text":112,"@type":113},"To compare demographics, clinical characteristics, stroke mechanisms, and long-term outcomes between acute ischaemic stroke patients with active cancer and those without cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were active and non-cancer patients defined and selected?",{"text":117,"@type":113},"Patients with active cancer (including previously known and newly diagnosed cancers) were included, while patients with inactive cancer were excluded, using registry data from 2003–2021 with propensity score matching.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes differed between active cancer and non-cancer groups?",{"text":121,"@type":113},"Three-month modified Rankin Scale scores were not significantly different, but at 12 months active cancer was associated with higher risk of death and cerebrovascular recurrence, both before and after matching.",{"name":123,"@type":110,"acceptedAnswer":124},"What clinical implication did the authors suggest?",{"text":125,"@type":113},"Antithrombotic medications at discharge may reduce the subsequent one-year risk of death and cerebrovascular recurrence in patients with active cancer.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336447,1790145556,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","DOI: 10. 1111/ene.16200  \nOR I G I NAL ART I C L E  \nAcute ischaemic stroke in active cancer versus non-cancer patients: stroke characteristics, mechanisms and clinical outcomes  \nGianluca Costamagna1,2  | Andreas F. Hottinger3 | Haralampos Milionis4  | Alexander Salerno1  | Davide Strambo1 | Francoise Livio5 | Babak B. Navi6,7 | Patrik Michel1  \n1Stroke Center, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland  \n2Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy 3 Lundin and Family Brain Tumor Research Center, Services of Neurology and Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland  \n4First Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece  \n5Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland  \n6Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York City, New York, USA  \n7Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA  \nCorrespondence  \nGianluca Costamagna, Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Via Francesco Sforza 35, 20122, Milan, Italy. [Email:](Email: gianluca.costamagna@unimi.it)[ gianluca.costamagna@unimi.it](Email: gianluca.costamagna@unimi.it)  \nAbstract  \nBackground and purpose: Demographics, clinical characteristics, stroke mechanisms and long-term outcomes were compared between acute ischaemic stroke (AIS) patients with active cancer (AC) versus non-cancer patients.  \nMethods: Using data from 2003 to 2021 in the Acute STroke Registry and Analysis of Lausanne, a retrospective cohort study was performed comparing patients with AC, including previously known and newly diagnosed cancers, with non-cancer patients. Patients with inactive cancer were excluded. Outcomes were the modified Rankin Scale (mRS) score at 3 months, death and cerebrovascular recurrences at 12 months before and after propensity score matching.  \nResults: Amongst 6686 patients with AIS, 1065 (15 .9%) had a history of cancer. After excluding 700 (10 .4%) patients with inactive cancer, there were 365 (5 . 5%) patients with AC and 5621 (84%) non-cancer AIS patients. Amongst AC patients, 154 (42 . 2%) strokes were classified as cancer related. In multivariable analysis, patients with AC were older (adjusted odds ratio [aOR] 1.02, 95% confidence interval [CI] 1.00–1.03), had fewer vascular risk factors and were 48% less likely to receive reperfusion therapies (aOR 0 . 52, 95% CI 0.35–0.76) . Three-month mRS scores were not different in AC patients (aOR 2 . 18, 95% CI 0.96–5.00) . At 12 months, death (adjusted hazard ratio 1 .91, 95% CI 1.50–2.43) and risk of cerebrovascular recurrence (sub-distribution hazard ratio 1. 68, 95% CI 1.22–2. 31) before and after propensity score matching were higher in AC patients.  \nConclusions: In a large institutional registry spanning nearly two decades, AIS patients with AC had less past cerebrovascular disease but a higher 1-year risk of subsequent death and cerebrovascular recurrence compared to non-cancer patients. Antithrombotic medications at discharge may reduce this risk in AC patients.  \nK E Y WO R D S  \nantithrombotics, cancer, cerebrovascular recurrences, ischaemic stroke, mortality  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.  \nINTRODUCTION  \nBetween 4% and 20% of patients with acute ischaemic stroke (AIS) have comorbid cancer","cbCaimJAFVSa0lqB","https://ap.wps.com/l/cbCaimJAFVSa0lqB","pdf",1499408,12,"English","# Abstract\n## Background and purpose\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Cancer as a comorbidity in AIS\n## Distinct stroke characteristics in active cancer\n## Cryptogenic mechanisms and hypercoagulability\n## Gaps in previous studies","[{\"question\":\"What was the study’s main goal?\",\"answer\":\"To compare demographics, clinical characteristics, stroke mechanisms, and long-term outcomes between acute ischaemic stroke patients with active cancer and those without cancer.\"},{\"question\":\"How were active and non-cancer patients defined and selected?\",\"answer\":\"Patients with active cancer (including previously known and newly diagnosed cancers) were included, while patients with inactive cancer were excluded, using registry data from 2003–2021 with propensity score matching.\"},{\"question\":\"What outcomes differed between active cancer and non-cancer groups?\",\"answer\":\"Three-month modified Rankin Scale scores were not significantly different, but at 12 months active cancer was associated with higher risk of death and cerebrovascular recurrence, both before and after matching.\"},{\"question\":\"What clinical implication did the authors suggest?\",\"answer\":\"Antithrombotic medications at discharge may reduce the subsequent one-year risk of death and cerebrovascular recurrence in patients with active cancer.\"}]","Acute ischaemic stroke in active cancer versus non-cancer patients: stroke characteristics, mechanisms and clinical outcomes | PDF",1790015086,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1808f66a2f0bed2e4c654aac4500c6a6.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/049715a17627baaae075c09432b8e28a.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d62c58a868173cc51e8c0057245a51b9.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d61382016d2d286f741744916d23c487.webp",980,1287]